Your browser doesn't support javascript.
loading
Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.
Huezo-Diaz Curtis, P; Uppugunduri, C R S; Muthukumaran, J; Rezgui, M A; Peters, C; Bader, P; Duval, M; Bittencourt, H; Krajinovic, Maja; Ansari, Marc.
Afiliação
  • Huezo-Diaz Curtis P; Department of Pediatrics, Onco-Haematology Unit, Geneva University Hospital, Geneva, Switzerland.
  • Uppugunduri CRS; CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Muthukumaran J; Department of Pediatrics, Onco-Haematology Unit, Geneva University Hospital, Geneva, Switzerland.
  • Rezgui MA; CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Peters C; UCIBIO@REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.
  • Bader P; Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, Quebec, Canada.
  • Duval M; St Anna Children's Hospital, Vienna, Austria.
  • Bittencourt H; University Hospital for Children and Adolescents, Frankfurt/Main, Germany.
  • Krajinovic M; Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, Quebec, Canada.
  • Ansari M; Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada.
Pharmacogenomics J ; 18(1): 64-69, 2018 01.
Article em En | MEDLINE | ID: mdl-27779248
ABSTRACT
Sinusoidal obstruction syndrome (SOS) is a severe complication of hematopoietic stem cell transplantation (HSCT) that can be fatal, often attributed to the conditioning regimen prior to HSCT. We evaluated the association of SOS risk with gene variants in cystathionase (CTH), an enzyme involved in glutathione synthesis, in 76 children receiving intravenous busulfan (Bu) before HSCT. Our results indicated an association with CTHc.1364 G>T (ORTT=10.6, 95% confidence interval (CI)=2.16, 51.54) and SOS risk, which was sex dependent (female patients, ORTT=21.82, 95% CI=3.590-132.649). The interaction between CTHc.1364 G>T and another risk variant (GSTA1*B) was explored. A recessive model with the use of GSTA1*B*B and CTH c.1364 TT genotypes proved to be useful at predicting SOS occurrence, indicating the possibility of using these gene variants as markers of SOS occurrence and to further individualize preemptive treatment aimed at reducing SOS incidence.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Hepatopatia Veno-Oclusiva / Bussulfano / Ciclofosfamida / Cistationina gama-Liase / Glutationa Tipo de estudo: Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Hepatopatia Veno-Oclusiva / Bussulfano / Ciclofosfamida / Cistationina gama-Liase / Glutationa Tipo de estudo: Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Ano de publicação: 2018 Tipo de documento: Article